Spots Global Cancer Trial Database for A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
Official Title: A Phase 1b Study of ZN-c5 in Combination With Abemaciclib in Patients With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
Study ID: NCT04514159
Conditions
Study Description
Brief Summary: This is a Phase 1b, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-c5 administered orally in combination with abemaciclib (VERZENIO®) in participants with advanced estrogen-receptor positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site 2, Gilbert, Arizona, United States
Site 1, Charleston, South Carolina, United States
Site 6, Grudziądz, , Poland
Site 4, Kraków, , Poland
Site 5, Łódź, , Poland
Contact Details
Name: Carrie Brownstein, MD
Affiliation: Zeno Alpha Inc.
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
